Manage Your Liver
Q:

Why is the hepatitis C virus (HCV) so difficult to kill?

A:

The hepatitis C virus (HCV) infects millions of people worldwide. Patients are desperate for an effective treatment but medical professionals and the pharmaceutical industry have yet come up with the ideal one. There are two main reasons why HCV is so hard to kill.

 

First, HCV knocks out the host’s innate immunity. By constant mutation, HCV may be able to escape detection and elimination by the host’s immune system. [1] Therefore, it is almost impossible for the host to kill the virus without external help.

 

Second, HCV is highly mutable. HCV is an RNA virus and lacks proofreading ability as it replicates, therefore dozens of mutated forms arise. Even within an individual, slightly different genetic versions of HCV are present. According to WHO, there are at least 11 HCV genotypes identified throughout the world. The genotype is the strain of the virus to which patients were exposed when they were infected. [1]

 

The genotype generally does not affect the progression of liver diseases. However, it is of great clinical importance; different genotypes vary in their responsiveness to HCV treatments. For example, compared with genotype 1, patients with genotypes 2 and 3 are more likely to achieve a sustained virological response to interferon/ribavirin therapy. In addition, therapy duration also varies among different genotypes. Patients with genotypes 2 or 3 generally are treated with combination therapy for only 24 weeks, while patients with genotype 1 usually receive treatment for 48 weeks. [2]

 

Traditionally, combination therapy with interferon/ribavirin is recommended for HCV patients. Interferons do not directly kill the virus; instead they boost the immune system response to attack the virus. The success rate for such therapy is very low and often comes with unbearable side effects such as fever, headache and other flu-like symptoms. [3]

 

In recent years, new medications for HCV were developed. One of the most promising is Harvoni, a direct-acting antiviral (DAA) medication. Unlike interferon, DAAs directly inhibit the ability of HCV to replicate. Harvoni is a combination of two DAAs where one interferes with the reproduction of the virus’s genetic material, while the other interferes with a protein needed to complete the virus life cycle in the liver cell.

 

Although Harvoni claims to have high success rates in clinical studies, not many patients can afford it due to its extremely high cost. Moreover, a person could get infected again even after successful treatment. [4]

 

Despite the introduction of new drugs, treatment options for hepatitis C patients are still limited. If patients are unable to receive antiviral treatment due to genotype or financial reasons, or have tried and failed, they should shift their treatment focus to protecting liver function and reducing inflammation (ALT).

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Tags:
Hepatitis CHep CHCVChronic Hepatitis CHarvoniInterferonRibavirin
Related Questions
A:
ALT (Alanine Aminotransferase / SGPT) is an enzyme that is mainly found in liver cells. The level of ALT in our bloodstream is the primary indicator of liver health. Multiple studies have demonstrated that the presence of an elevated ALT level is associated with increased liver-related mortality.   New normal ALT level issued The American College of Gastroenterology (ACG) recently issued a new Practice Guideline that aims to offer a framewor
A:
ALT (Alanine Aminotransferase / SGPT) is an enzyme that is mainly found in liver cells. The level of ALT in our bloodstream is the primary indicator of liver health.   What does high ALT indicate? ALT enzymes are normally contained within liver cells when the liver is healthy, but when the liver cells are injured or damaged by whatever means, ALT enzymes are released into the bloodstream, causing levels to go up. Therefore, by measuring the
Hit Questions
A:
Cancer is a leading cause of morbidity and mortality in the United States and results in a high economic burden. A recent research published by The JAMA Network has reveal that cancer mortality declined overall in the United States between 1980 and 2014. And the number of deaths for nearly all forms of cancer has decreased significantly, but not for liver cancer, kidney cancer and non-Hodgkin lymphoma (NHL) cancer.   Deaths due to NHL and kidney cancer remained the sa
A:
Recent research by the University of Edinburgh have gained new insight into how common painkiller paracetamol causes liver damage. The research studied the impact of paracetamol on liver cells in human and mouse tissue.   Toxicity liver damage is currently the leading cause of acute liver failure in the Western world. Long term or excessive use of paracetamol can damage the liver by harming vital structural connections between cells. One of the common result of toxici
A:
Fatty liver is on the rise and it is quickly becoming one of the most worrying disease in developed countries, a condition that most Americans have never heard of and now experts say as many as one in three of us may be at risk. Fatty liver disease is a gradual killer which often shows no symptoms until it develops into a much server problem like: cirrhosis - a condition that could lead to liver cancer or death.   Douglas Denham is medical director at Clinical Trials
A:
ALT (Alanine Aminotransferase / SGPT) is an enzyme that is mainly found in liver cells. The level of ALT in our bloodstream is the primary indicator of liver health. Multiple studies have demonstrated that the presence of an elevated ALT level is associated with increased liver-related mortality.   New normal ALT level issued The American College of Gastroenterology (ACG) recently issued a new Practice Guideline that aims to offer a framewor
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us